

New NICE proportionate approaches: Are they any faster or more successful?

Rebecca Andrews, Doug Hall, Richard Macaulay

ISPOR EU, 15th November 2023

PRECISION**advisors**



Precision Value & Health offers a range of specialised, yet complementary capabilities across the commercialisation continuum for pharmaceutical products

Introductions



PRECISION**effect**

DRIVING BRAND ADOPTION

PRECISION**xtract**

UNLOCKING DATA
PERSONALIZING ENGAGEMENTS

PRECISION**advisors**

OPTIMIZING GROSSTO NET

PRECISION**scientia**

COMMUNICATING THE SCIENCE

PRECISION**heor**

ESTABLISHING EVIDENCE

PRECISION**value**

ENABLING ACCESS



Richard Macaulay, Senior Vice President,
Global Pricing & Market Access, PRECISIONadvisors

Richard is responsible for the growth and development of consultative, analytic, and data services supporting life science products' commercial performance. Our team excels at understanding the ever-changing and complex healthcare market and helping clients solve issues including access strategy, stakeholder mapping, value communication, strategic pricing, and product positioning.


Agenda

1	What is the NICE proportionate approach?
2	Are NICE proportionate approach appraisals quicker?
3	Does NICE proportionate approach improve outcomes?
4	Conclusions

NICE introduced a new proportionate approach in April 2023 to allow for more rapid and efficient evaluations

What is NICE proportionate approach?

The NICE proportionate approach is aimed at **increasing efficiency of the appraisal process**; the approach is **split into two phases** and includes **multiple new appraisal pathways** which have been piloted by preselected products, in addition to **overarching changes that will be applied to all appraisals**



NICE used 7 products to pilot the three appraisal processes in part 1 and is currently piloting the 'pathway appraisal' process in part 2

Four different appraisal pathways are currently being piloted

		<u>Pilots</u>
Cost-comparison	Streamlined economic analysis for technologies that are likely to provide similar health benefits to technologies already recommended by NICE	<ul style="list-style-type: none">➤ Somatrogen➤ Vutrisiran
Stream-lined decision making	Shortened appraisal process applicable to all technologies considered low decision uncertainty	<ul style="list-style-type: none">➤ Nivolumab➤ Nintedanib➤ Eptinezumab
Paired appraisals	Improved internal approaches to manage technologies in the same disease area with similar timelines	<ul style="list-style-type: none">➤ Dapagliflozin➤ Empagliflozin
<hr/>		
Pathway appraisals	Combine several medicines across an entire disease pathway with a centralised economic model	<ul style="list-style-type: none">➤ Cabozantinib w/ nivolumab

Six products have undergone NICE proportionate approach, with two more being assessed; all six products were recommended in an average of 36 weeks


NICE proportionate approach pilot products

Type of appraisal	Pilot products	Appraisal date	Outcome	Appraisal duration
Cost-comparison	Somatrogon	14 Jul 2022	<i>Recommended</i>	36 weeks
	Vutrisiran	14 Sep 2022	<i>Recommended</i>	22 weeks
Streamlined decision making	Nintedanib	08 Apr 2022	<i>Recommended (optimised)</i>	40 weeks
	Nivolumab	14 Jul 2022	<i>Recommended</i>	35 weeks
	Eptinezumab	16 Jun 2022	<i>Recommended</i>	36 weeks
Paired appraisals	Dapagliflozin	12 Jul 2022	<i>Recommended</i>	49 weeks
	Empagliflozin	12 Jul 2022	<i>Ongoing</i>	Expected: 68 weeks
Pathway appraisals	Cabozantinib with nivolumab	13 Feb 2023	<i>Ongoing</i>	Expected: TBC

The average appraisal time was 73 weeks (IQR 50-90 weeks) for all 2021/2022 appraisals; positive appraisals are slightly faster, taking an average of 71 weeks

Duration of NICE appraisals


Average duration of NICE appraisals in 2021/2022 period (n=104)



The average time between ‘invitation to participate’ and publication for the five NICE proportionate approach pilots was 36 weeks (range: 22-49 weeks)

Are NICE proportionate approach appraisals quicker?


Duration of NICE appraisals



In 2021/2022, 104 NICE appraisals were identified, and the majority of outcomes were found to be positive (recommended, optimized, CDF)

Outcomes of NICE appraisals

Outcomes of NICE appraisals in 2021/2022 period (n=104)



Positive outcomes breakdown	
Recommended	43%
Optimised	53%
CDF	11%

All proportionate approach pilots received positive outcomes (five recommended and one optimized), which is higher than the average outcomes in 2021/2022

Does NICE proportionate approach improve outcomes?

Type of appraisal	Pilot products	Outcome
Cost-comparison	Somatrogon	Reimbursed
	Vutrisiran	Reimbursed
Streamlined decision making	Nivolumab	Reimbursed
	Nintedanib	Reimbursed (optimised)
	Eptinezumab	Reimbursed
Paired appraisals	Dapagliflozin	Reimbursed
Overall outcomes for pilot products		100% positive 83% recommended 17% optimised

**All 2021/2022
NICE outcomes:**
71% positive
43% recommended
53% optimised

Our analysis suggests products assessed via the NICE proportionate approach received faster appraisals and better outcomes

Conclusions



Outcomes

All six pilots received positive outcomes via NICE proportionate approach



Timing

NICE's proportionate approach accelerated the assessment of products by an average of 37 weeks



Caveat

The pilot assessments were intended to test the viability of this approach and the products assessed are likely to have been carefully selected



Ongoing pilots

It will be interesting to monitor outcomes of ongoing pilot products and subsequent use of NICE's proportional approach to see the extent of impact

THANK YOU!

we look forward to staying in touch

PRECISION**advisors**
a precision value & health team